But there would be harm to the plaintiff, CYDY, if

But there would be harm to the plaintiff, CYDY, if Amarex weaseled out of paying an award to CYDY, and a case can be made that Amarex’s and NSF’s corporate interests are in fact the same, given that NSF — CONTROLS — Amarax. NSF certainly “dominates” Amarex if they have one of NSF’s people as CEO, NSF has at least 2 board seats, and the NSF CEO has taken personal control over at least one aspect of Amarex. That aspect being, of course, the “investigation” that he promised Nader, which he then either took no action on, or squelched.

The NSF CEO’s personal involvement in and of itself is a powerful argument for piercing the corporate veil.